Neil M. Schultz - Concepedia

Author

Neil M. Schultz

Astellas Pharma (United States)

Also Known As

N. Schultz, N.M. Schultz, Neil M Schultz, Neil M. Schultz, Neil Schultz

Publications

829

Citations

H-Index

Concepts

All Affiliations

Astellas Pharma (United States)Pfizer (United States)Duke University STATinMED (United States)Astellas Pharma (United Kingdom)

About

Neil M. Schultz is an author at Astellas Pharma (United States) specializing in medicine, urology, and outcomes research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	95
2	Health Sciences	1	1	33
3	Public Health	1	1	12
4	Health Policy	1	1	12
5	Surgical Oncology	1	1	35

Neil M. Schultz

Publications

620

Citations

H-Index

Page 1

	Year	Citations
Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden Rossella E. Nappi, Robin Kroll, Emad Siddiqui, Menopause The Journal of The North American Menopause Society	2021	181
Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey Rossella E. Nappi, Emad Siddiqui, Lora Todorova, Maturitas	2022	59
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate Scott T. Tagawa, Krishnan Ramaswamy, Ahong Huang, Prostate Cancer and Prostatic Diseases	2021	57
Effect of DETOX as an adjuvant for melanoma vaccine Neil M. Schultz, Ruth Oratz, Dunlu Chen, Vaccine	1995	46
Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. Megan McNamara, Daniel J. George, Krishnan Ramaswamy, Journal of Clinical Oncology Surgical OncologyCancer ManagementEpidemiology Of CancerPharmacotherapyOverall Survival	2019	35
Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis Neil M. Schultz, Scott C. Flanders, Samuel Wilson, Advances in Therapy UrologyHealth EconomicsEmergency Department CostsMedicineAbiraterone Acetate	2018	33
Clinical and economic burden associated with stage III to IV triple‐negative breast cancer: A SEER‐Medicare historical cohort study in elderly women in the United States Kendra Schwartz, Michael S. Simon, Lauren C. Bylsma, Cancer	2018	32
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer Daniel J. George, Krishnan Ramaswamy, Ahong Huang, Prostate Cancer and Prostatic Diseases	2021	30
Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States Petra Stute, Antonio Cano, Rebecca C. Thurston, Maturitas	2022	24
The Patient Experience: Symptoms and Impact of Dry Age-Related Macular Degeneration Neil M. Schultz, Lydia Braunack-Mayer, Jason J. Schwartz, Ophthalmology and Therapy	2021	19

Page 1